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Blood Lymphocytes 
Frank W. Symington and Erlinda B. Santos 
C linical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, U .S.A. 
Interleukin 2 (IL-2) - activated peripheral blood mononu-
clear cells (PBMC) have been reported to lyse tumor cells 
w hile essentially sparing normal cells in vitro. This report 
concerns IL-2- induced anti-keratinocyte (anti-KC) cyto-
toxic effectors that lyse normal human keratinocytes (KC) in 
vitro. Effectors were generated by culturing PBMC for 1-
8 din various concentrations of recombinant IL-2 and then 
assayed against 51Cr-labeled targets. Effectors stimulated 
w ith 103 U /ml of IL-2 for 8 d readily lysed adherent or 
trypsinized autologous or allogeneic KC cultured in serum-
free medium. Induction of anti-KC effectors was IL-2 dose-
dependent, with as little as 12 - 25 U/ml of IL-2 inducing 
increased anti-KC activity after 24 h of treatment. Although 
anti-KC activity was increased after overnight culture in 
IL-2, maximal effector potency in terms of lytic units (LU) 
per 106 effector cells required 4 d ofiL-2 treatment. Maximal 
effector yield in terms of LU per input PBMC occurred after 
8 d of IL-2 treatment. Antibody plus complement depletion 
I t has recently become clear that keratinocytes (KC) interact extensively with the immune system during health and in response to disease or injury. Histologic evidence of these interactions includes the continual presence of marrow-derived Langerhans cells and certain T lymphocytes among 
KC in healthy epidermis (1,2] . Immune cells and KC also interact 
via secreted cytokines. For example, KC produce potent immuno-
modulatory cytokines such as IL-1, colony-stimulating factors, and 
transforming growth factors alpha and beta [3 - 7] . Keratinocytes, in 
turn, are exquisitely sensitive to immune cell products such as inter-
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Abbreviations: 
C': complement 
IFN-g: interferon gamma 
IL-2: interleukin 2 
KC: keratinocytes 
KC-A (KC-B, KC-C, etc.): keratinocytes from individual A (B, C, etc.) 
LAK: lymphokinc-activated killers 
LU: lytic units 
NK: natural killer 
PBMC: peripheral blood mononuclear ce lls 
studies showed that the anti-KC effectors predominantly 
have a CD16 -jCD3 -jCD2 +phenotype. A natural killer 
(NK) - like specificity of the effectors was suggested by two 
findings: unlabeled K562 cells totally inhibited lysis of StCr-
KC in cold target competition assays, and interferon gamma 
(IFN-g) treatment (2.5 U/ml-500 U/ml of recombinant 
IFN-g for 48-72 h) down-regulated KC susceptibility to 
lysis by these effectors. Thus, IL-2 treatment of PBMC in-
duces non- T cell, natural killer -like effectors that can lyse 
both autologous and allogeneic KC. Furthermore, KC resem-
ble other cell types that becom e resistant to non - MHC-
restricted lysis after treatment with IFN-g. Finally, the con-
trasting effects of IFN-g treatment on KC lysis by these 
effectors, as opposed to lysis by specific T cells, suggests that 
IFN-g could promote a shift from non - MHC-restricted to 
MHC-restricted KC lysis during epidermal immune re-
sponses in vivo.] Invest Derma tol96:---. 1991 
feron gamma (IFN-g), tumor necrosis factor alpha, lymphotoxin, 
and transforming growth factor beta [8 - 10]. Among those interac-
tions involving direct intercellular contact benveen lymphocytes 
and KC, those that culminate in KC lysis are of considerable interest 
for their possible roles in mediating skin disease characterized by 
lymphoid infiltrates and KC damage (11-13] . In vitro studies have 
identified several distinct cellular effector mechanisms of KC lysis . 
Monocytes and certain lymphocytes can lyse KC in an antibody-de-
pendent fashion (14] . Cultured cytotoxic T-cell (CTL) lines and 
HLA-specific CTL clones can lyse KC via recognition of major 
histocompati~ility compl~x (MHC) antigens or other alloantigens 
[15,16). The tmmunolog1c spectfic1ty of these two mechanisms of 
cell-mediated KC lysis is conferred by well-characterized receptors 
produced by B and T lymphocyte clones, respectively. 
A third cytotoxic effector mechanism was recently described in 
which recognition and lysis of KC aepears to involve other, as-yet 
undefined, mechanisms [17] . These effectors were induced by treat-
ment of peripheral blood mononuclear cells (PBMC) with IL-2, and 
they lysed KC in the absence of exogenous antibody and in a non-
MHC-restricted fashion [17]. The idea that similar effector cells 
might be induced in vivo by endogenous or therapeutic IL-2 affords 
a potential explanation for skin damage associated with bone-
marrow transplantation and IL-2 therapy, respectively [ 12,18, 19], 
and such effectors could conceivably lyse virus-infected or trans-
formed KC. The present studies provide further information about 
the induc~ion and ?'ature of this novel effector activity. Specifically, 
thes~ studie.s exa1m~e~ the IL-2 dose and exposure interval required 
to e!tctt antt-KC actiVIty, the phenotype and specificity of the effec-
tors, and the effects ofKC exposure to IFN-g on their susceptibili ty 
to lysis by IL-2-stimulated PBMC. 
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MATERIALS AND METHODS 
Cytokines and Antibodies Recombinant human IL-2 (IL-2) 
was kindly provided by Hoffman La Roche, Inc. (Nutley, NJ). 
Recombinant human IFN-g preparations generously supplied by 
Dr. G. Seelig (Shering Corp., Bloomfield, NJ) and Shionogi Phar-
maceutical Company (Osaka City,Japan) were stored at -70oC m 
3% human serum albumin until use. Ascitic fluid containing hybri-
doma antibodies against CD3 (38.1, IgM), and purified antibodies 
against CD2 (35.1, IgG2a) and CD16 (Fcl, IgM; Fc2, IgG2a) were 
gifts of Drs . P. Martin and C. Anasetti (Fred Hutchinson Cancer 
Research Center) and Dr. E. Clark (University of Washington, 
Seattle, W A), respectively. 
Generation of Effector Cells Human peripheral blood mono-
nuclear cells (PBMC) were purified from heparini~ed blood by 
Ficoll-Hypaque separation. Cells were washed three Urnes and cul-
tured at 1 X 106 ml in RPMI1640 containing 10% pooled human 
serum (PHS) or 10% feta l bovine serum (FBS) (Hyclo~e, Logan, 
UT), as indicated. Effector cells were generated by cu_ltunng PBMC 
for 1-8 din as much as 103 U/ml of human recombmant IL-2. For 
those effectors generated by 8 d of culture in103 U /ml ofiL-2, 80% 
of the culture medium was replaced with fresh medium containing 
103 U /ml ofiL-2 on day 6, and the cultures split fivefold on day 7 
into fresh, IL-2-containing medium. Effector populations were 
frozen in 95% FBS, 5% DMSO for storage in liquid nitrogen until 
use. 
Target Cell Culture Basal K~ were released by t~psinizing 
epidermal sheets ob~amed by suctiOn b10p_sy of adu~t skm, by o:rer-
night Dispase digestion of neonatal foreskm as prev10usly de~cnbed 
(9], or by similar digestion of trimmed 3-mm punch b10ps1es ob-
tained following informed consent according to protocols approved 
by the Institutional Review Board of the Fred Hutchinson Cancer 
Research Center. Keratinocytes were cultured in coml?lete 
MCDB 153 serum-free medium with modifications (20,21 j, as 
previously described [9], using recombinant human epi?ermal 
growth factor genero~sly supplied by C. G~or~es-Nasc1mento 
(Chiron Corp., Emeryvtlle, CA). Except where md1cated, KC were 
used at second throug~ fourth passag~ (2-4 ':"eeks of cu_lt~re). Kera-
tinocytes were sometimes cultured m medmm contammg IFN-g 
(2.5 - 500 U jml) for 48-72 h before use in cytotoxicity assays. The 
K562 and Daudi cell lines were kindly provided by T. Papayanno-
poulou (University of Washington) and I. Bernstein (Fred Hutchin-
son Cancer Research Center), respectively, and were cultured in 
RPMI1640 containing 10% FBS. 
Cytotoxicity Assays Effector cells were t~awed, :washed twice, 
and resuspended to 1- 6 X 106 cells per ml m mod1fied complete 
MCDB153. These suspensions and five twofold di lutions thereof 
were plated in triplicate in 96-well round-bottom !?late wells (~00 
.ulfwell) (Flow Laboratories, McLean, VA). For antibody depletiOn 
studies, effectors were incubated on ice at 107 cells per m l for 20 mm 
with 20 .ug/ml of antibody or di luent before adding an equal vol-
ume of twofold diluted, pre-tested rabbit serum (C') and incubating 
for 40 min at 3r. Cytotoxic treatment of peripheral blood lympho-
cytes with anti-CD3, anti-CD2, or anti-CD16 antibodies led to 
specific lysis of approximately 80%, 95%, and 10%-20% of cells, 
respectively. Viabilities and recoveries of treated cells were assessed 
by phase-contrast microscopy before and after recovery of viable 
cells by Ficoll-Hypaque centrifugation. The washed cells were ad-
justed to the same concentrations of viable cells, as described above 
for untreated cells, and then plated. For target cell radiolabeling, 
cells were resuspended in PBS diluted 1 : 1 with either complete 
MCDB 153 (KC) or RPMI1640 with 30% FBS (K562, Daudi), and 
incubated for up to 75 min at 37°C with 0.25 mCi/ml to 0.5 
mCi/ml of S1Cr (Du Pont-New England Nuclear) . Labeled cells 
were washed three times and resuspended in modified complete 
MCDB153 to 2 X 104 cells/ml (KC) or 4 X 104 cells/ml (K562, 
Daudi) . Incorporated radioactivity was always> 5 cpm/cell for KC 
and > 2 cpm/ cell for K562 and Daudi. For cold target competition 
experiments, labeled target cells at twice these concentrations were 
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Table I. Lysis of Autologous and Allogeneic Keratinocytes by 
IL-2-Stimulated PBMC 
LU20• Against 
Experiment Effector Auto-KCb Allo-KC Daudi 
Auto-LAK 101 214 64 
Auto-PBMC 7 9 1 
2 Auto-LAK 84 94 18 
Auto-PBMC <1 n.d.' <1 
3 Auto-LAK 27 38 61 
Auto-PBMC 2 2 n.d. 
4 Auto-LAK 25 52 n.d. 
5 Auto-LAK 43 67 6 
6 Auto-LAK 37 117 10 
'Cytotoxic activities of IL-2-stimulated and unstimulated PBMC were tested in 
triplicate assays against 51 Cr-labeled, trypsinizcd KC at six, decreasing twofold E: T 
ratios starting at 150 : 1 or 120 : 1, and against labeled Daudi at ratios starting at 60: 1 or 
30 : 1. Specific lysis values were analyzed to determine LU20 per 10• cells as described in 
Materials a11d Methods. 
'The prefix "auto" is used to denote syngeneic cells within a given experiment. LAK 
refers to PBMCstimulared with 10' U/ml ofiL-2 for 8 d. Allo-KC denotes KC from 
individuals unrelated to the effector cell donor. 
' Not determined. 
mixed with equal volumes of different dilutions of unlabeled cells to 
yield 30: 1, 10: 1, 3.3: 1, and 0 : 1 ratios of unlabeled: labeled cells. 
In some cases, target cells were preincubated with dialyzed human 
laminin (20 .Ug/ml) (BRL, Bethesda, MD) or synthetic YIGSR-
NH2 peptide (up to 2 mgjml) (synthesized by E. Tolentino, Fred 
Hutchinson Cancer Research Center) before plating them into the 
assay. In all cases, 100 .ul of target cells were added to wells contain-
ing effector cells, medium only, or 0.2% NP-40 detergent. Plates 
were then centrifuged 2 min at 15 X g, floated for 5 min in a 3 r C 
water bath, and incubated for 4 h in humidified 7% C02, 93% air. 
Plates were centrifuged for 2 min at 200 X g and the radioactivity in 
100 .ul of supernatant from each well was determined in a Packard 
gamma counter. 
Data Analysis Percent specific lysis (SL) values were calculated 
by using the formula, %SL = ((ER- SR)/(DR - SR)] X 100%, in 
which ~R, SR, and DR rel?resent supernatant radioactivity in wells 
contammg effectors, medium only, or detergent, respectively. A 
computer program generously provided by Dr. H. Pross (McGill 
University, Ontario, Canada) was used to calculate lytic units (LU) 
per 106 effectors for each combination of effector and target cells 
according to an exponential fit formula [22]. The LU calculated for 
10% or 20% levels of lysis are presented as LU 10 or LU20 , respec-
Table II. Time and IL-2 Dose Requirements for the Induction 
of Anti-KC Effectors 
A. 
Days of Treatment, 1000 lJ jml IL-2 
2 4 6 8 
6 (5)• 14 (10) 101 (46) 119 (238) 60 (336) 
B. 
IL-2 dose Days of Treatment 
(Ujml) 2 3 
0 2 (1.5) 1 (0.8) < 1 (n.d.b) 
0.2 2 (1.4) 1 (1.0) < 1 (n.d.) 
1 2 (1. 7) 1 (0.8) < 1 (n.d.) 
5 2 (1.6) 2 (1.5) 2 (1.2) 
25 7 (4.9) 10 (6.0) 36 (19.5) 
125 5 (3.7) 9 (5.6) 24 (15 .2) 
' Results for A and B are expressed as LU20 per 106 effectors, with the yield of LU,. 
per 10• input PBMC given in parentheses. 
'Not determined. 
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tively. Differences in LU calculated for a given effector population 
against non-treated vs IFN-g-treated KC were considered to reflect 
differences in their susceptibility to lysis. 
RESULTS 
IL-2-Treated PBMC Lyse Allogeneic and Autologous 
l{C Treatment ofPBMC with 103 U /ml of recombinant IL-2 for 
8 d led to cell proliferation and the induction of cytotoxic anti-KC 
effectors that lysed allogeneic and autologous KC (Table I). Of the 
17 effector popu lations from different donors that were assayed 
against both autologous and allogeneic KC, all 11 that demon-
strated more than ten LU20 against allogeneic KC also lysed autolo-
gous KC. Detection ofKC lysis by IL-2-stimulated PBMC did not 
require the use of suspensions of trypsinized KC, as videomicro-
graphic assays showed that these effectors also killed adherent KC 
(data not shown). Effectors were generated in medium containing 
only human serum, and they were assayed in serum-free medium 
against KC grown in serum-free medium. Therefore, effector gener-
ation and KC lysis did not require heterologous serum proteins, and 
KC lysis was independent of human serum antibodies or other 
serum components in the assay. In addition, the fact that KC targets 
were cultured from fresh epidermal isolates of both normal adult 
and neonatal skin indicates that KC lysis did not depend on ex-
tended periods of culture or the age of the cells. 
Three kinds of variation were noted in the generation and assay of 
these anti-KC effectors. First, the percent of input cells recovered 
after the above IL-2 treatment ranged from 50%-810% 
(median= 275%) for PBMC from 26 healthy individuals . Second, 
the potency of different effector populations differed. To a certain 
extent, anti-KC potency and IL-2-driven PBMC proliferation 
seemed to vary inversely. For example, cell recoveries of 240 ± 
150% (mean± SD) were obtained for the 17 effector populations 
that yielded > 30% specific lysis at maximum E: T ratios, as com-
pared to 500 ± 165% for the nine populations that yielded $30% 
lysis. A direct test of this trend was not attempted because of the 
third variation, which was that the maximum plateau-specific lysis 
calcu lated for different KC sublines ranged from 40-85%. These 
differences did not reflect KC passage number (2-10 passages) or 
degree of culture confluence for subcultured primary KC isolates 
from the same donor. 
Time and IL-2 Dose Requirements for the Generation of 
Anti-KC Effectors The time needed to generate anti-KC effec-
to.J,'S was studied by assaying PBMC cultured in 103 U / ml ofiL-2 for 
1, 2, 4, 6, or 8 d against allogeneic KC derived from a single donor. 
Each assay day utilized aliquots of KC from the same passage that 
had been thawed and cultured for 3 d, in order to control for poten-
tial target cell differences. Table II (Part A} presents LU20 per 106 
IL-2 -stimulated effectors and also the yield of LU20 per 106 input 
PBMC for one such experiment. Maximum effector potency in 
terms of LU20 per 106 effector cells was reached after 4-6 d of 
cul ture in 1000 U jml of IL-2. Based on cell recoveries after IL-2 
stimu lation and the data in Table II (part A), however, the maximal 
yield ofLU20 was obtained after 8 d of culture. Similar results were 
obtained in two additional experiments in which effectors treated 
for different lengths of time were frozen and subsequently thawed 
and assayed on the same day against the same KC targets, although 
LU20 were reduced for these previously frozen effectors. 
Although titratable anti-KC activity was detected in some fresh 
PBMC preparations (e.g., Table I, Experimmt 1), this pre-existing 
activity was minimal. To investigate the IL-2 dose dependence of 
the induced anti-KC activity, PBMC were cultured in 125,25, 5, 1, 
0.2, or 0 U jml of IL-2 for 1, 2, or 3 d and assayed fresh against 
allogeneic KC as described above (Table liB). PBMC cultured in 1, 
0.2, or 0 U jml of exogenous IL-2 contained low-potency anti-KC 
effectors on day 1 that virtually disappeared by day 3 of culture. 
Only the 25 U /ml and 125 U /ml concentrations increased the 
potency of the anti-KC effectors during the first 3 d of culture. 
Similar results obtained in two other experiments showed that 12 
U/ml or more of!L-2 was needed to elicit anti-KC activity (data not 
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shown). Thus, the induction of increased anti-KC activity in 
PBMC strictly depends on exposure to at least 12-25 U/ml of 
exogenous IL-2 for 1 or more d. 
In the above experiments, high-dose IL-2 treatment induced 
anti-KC activity within 1 or 2 d, but the main increase in activity 
occurred after 3 or 4 d of culture (Table IIA,B). This could reflect 
either a need for effector cell proliferation or differentiation. Cell 
recoveries were similar for all of the tested IL-2 doses for effectors 
harvested after 1, 2, or 3d of culture. Increased numbers of cells 
were recovered only after more than 4 d of culture in high-dose 
IL-2. These findings suggest that if cell proliferation is responsible 
for increased anti-KC activity during the first 4 d of culture, then 
the proliferating cells are a small minority of the cultured PBMC. 
Anti-KC Effectors are Predominantly CD16 -jCD3 -j 
CD2 + Lymphocytes Treatment of PBMC with IL-2 leads to 
the expansion of several subsets of cells that can be distinguished by 
their expression of CD3 (associated with the T-cell receptor) and 
CD16 (low-affinity Fe receptor) [23,24]. To learn more about the 
subsets of IL-2- treated PBMC that lyse KC, effectors were treated 
with monoclonal anti-CD3 or anti-CD16 plus complement (C'), or 
with C' alone, and the surviving Ficoll-purified cells were assayed 
against SICr-labeled allogeneic KC, autologous KC, and K562 (Fig 
1). Compared to control C'-treated cells (solid bars), CD3-depleted 
effectors (striped bars) were somewhat enriched for lytic activity 
against these three targets. Based on the percent of cells specifically 
lysed by anti-CD3 plus C' and on viable cells recovered from this 
treatment in this experiment (30% and 94%, respectively), CD3 + 
cells accounted for fewer than 10% of the lytic units (LU20) present 
in the control effector population. Anti-CD16 plus C' (open bars) 
led to a small loss of anti-KC activity that represented approxi-
mately 10% of the total LU20 measured against allogeneic and auto-
logous KC. Similar results were obtained in two additional anti-
body-depletion experiments using anti-CD16 and anti-CD3. It 
should be noted that, although anti-CD16 plus C' treatment had 
little effect on K562 lysis by IL-2- activated effectors, similar treat-
ment of resting PBMC virtually eliminated anti-K562 activity, as 
was previously reported ([25]; data not shown). This difference in 
CD16 phenotype between anti-K562 effectors in resting and IL-2-
stimulated PBMC was expected, because IL-2 mainly expands a 
CD3 -jCD16- subset, and because CD3 -:-/CD16- cells in-
duced with similar IL-2 treatments were previOusly shown to lyse 
K562 [26]. The finding that CD16-depleted effectors still killed 
KC is additional evidence against a role for antibody-dependent 
cellular cytotoxicity in the observed lysis·. 
The expression of CD2 by anti-KC effectors was also examined 
(Table III). Here, PBMC activated for 6 d with 100 U j ml ofiL-2 
were treated with either anti-CD2 or anti-CD3 plus C' or with C' 
only. Anti-CD2 treatment specifically destroyed approximately 
85% of the anti-KC and anti-K562 activities (Table III). In similar 
experiments using PBMC activated for 8 d with 103 U/ml ofiL-2, 
anti-CD2 plus C' specifically lysed 93% of the effectors while de-
stroying 94% of input LU measured against both KC and K562. 
Thus, the predominant anti-KC effector here is a CD2+, non-T 
cell that expresses little or no FcRIII (CD16). 
Inhibition of KC Lysis by NK-Sensitive K562 Target Cells 
The phenotype and autocytotoxic function of these anti-KC effec-
tors suggested that they could have an NK-like specificity. To seek 
evidence of this, cold target competition experiments were per-
formed in which the effectors were titrated against a constant num-
ber of 51Cr-labeled KC admixed with different ratios of unlabeled 
KC or K562 (Fig 2) . Compared with control lysis in the absence of 
unlabeled targets (solid bars) , both KC (open bars) and K562 (diago-
nally striped bars) inhibited KC lysis at all three of the cold: hot target 
ratios tested. The K562 cells were approximately 3 times more 
inhibitory than homologous KC, because specific lysis in the pres-
ence of 3: 1 or 10: 1 unlabeled K562 was similar to lysis in the 
presence of 10: 1 or 30: 1unlabeled KC, respectively. Inhibition of 
KC lysis by unlabeled KC and K562 was specific, because a 30: 1 
excess of unlabeled Daudi cells (JJertically lined bars) yielded less 
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inhibition than tenfold fewer unlabeled KC and, as just mentioned, 
K562 was 3 times more active than KC. It could be argued that 
inhibition of KC lysis by unlabeled K562 was due to non-specific 
toxic effects of the anti-K562 interaction for a distinct anti-KC 
effector population. However, this inhibitory mechanism would 
itself have to be specific for the anti-KC effectors, as lysis of labeled 
Daudi by these same effectors was scarcely inhibited by even 30: 1 
ratios of unl abeled K562 (data not shown). Similar results were 
reproduced in thre~ additional experiment~ usi.ng KC ~nd effectors 
from different mdtvtduals. Because lammm-hke peptides on NK 
cells have been suggested to play a role in target lysis [27], we also 
Table Ill. Anti-KC Effectors are Predominantly 
CD2+/CD3-
Treatment 
C' only 
Anti-CD3 + C' 
Anti-CD2 + C' 
CI• 
57 
94 
Recovered LU20 
per 106 Input Cells 
55 (197)b 
60 (182) 
9 (33) 
%of Input 
LU20 Recovered 
100 (100) 
120 (92) 
16 (17) 
• Cytotoxic index (CI) is the percent of cells killed by complement in an antibody-dependent fashion. CJ ={AD- CD)/{!- CD) X 100%, where AD and CD equal the 
proportion of dead cells after treatment with antibody plus complement vs complement 
alone, respectively . 
1 Results arc expressed as LU20 per 106 effector cells as measured against KC and (in 
parentheses) K562. 
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Figure 1. Complement (C')-dependent immunodepletion was used to 
study the phenotype of the IL-2- induced effectors that lyse allogeneic KC (A), autologous KC (B) , and K562 (C). Effectors surviving treatment with 
C' only (solid bars), anti-CD16 (Fc1 + Fc2) plus C' (opw bars), or anti-CD3 {38.1) plus C' (striped bars) were titrated in triplicate into a 4-h cytotoxicity 
assay against these three S1Cr-labeled targets. Treatment with anti-CD3 or 
anti-CD16 plus C' specifically lysed 30% and 10% of these cells, respec-
tively. C' ~treated effectors had 69, 63, and 154 LU20 per 106 effectors when 
tested agamstallogenetc KC, autologous KC, and K562, respectively. Com-
parable LU20 were 56, 52, and 88 for an.ti - CD16-depleted cells, and 91, 83, 
and 154 for CD3-depleted cells. Triplicate assays were performed for this 
and all subsequent . figures presented, and these results are given as mean 
percent spectfic lym wtth error bars depicting SD greater than 10% of the 
mean. 
tested whether lysis of KC, which express laminin receptors, could 
be inhibited by intact laminin or laminin peptides. In four experi-
ments, KC lysis was not inhibited by soluble laminin (20 ,ug/ml) or 
YIGSR-NH2 (up to 500 ,ug/ml) , although the latter peptide is a 
receptor antagonist that can inhibit cell binding to laminin at these 
concentrations [28] (data not shown). 
IF~-g Treatment Reduces KC Susceptibility to Lysis by IL-2 
Activated PBMC Non-MHC-restricted lysis can be regulated 
by IFN-g [29-31; Diswssion] . Therefore, we investigated the ef-fec~s of IFN-g exposure on KC susceptibility to lysis by IL-2-
activated PBMC. For the results shown in Fig 3, cultured basal KC 
from three different donors were cultured in the presence (+) or 
absence of recombinant human IFN-g for 3 d before use as targets in 
51 Cr-release assays. The figure shows that IFN-g treatment induced 
each of the three KC populations to become resistant to lysis. Simi-
lar results wer.e obtained in seven other experiments involving KC 
from eleven different donors, six different effector populations, and 
two commercial sources of recombinant IFN-g (data not shown). 
Table IV indicates that treatment ofKC with as little as 2.5 U /ml of 
IFN-g for 2 d induced resistance to lysis by these effectors . A range 
of threefold to fifteenfold fewer LU20 were measured against IFN-g- treated KC than against control KC in these experiments overall. 
It was previously reported that IFN-g treatment enhances, rather 
than inhibits, KC lysis ofiL-2-activated effectors [17]. Unlike the 
effectors studied here, these other effectors were generated and 
assayed in the presence of FBS, and they were generated during 4 d 
of culture with 50 U jml of IL-2. To test whether these different 
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Figure 2. Unlabeled K562 and KC compete with 51 Cr-labcled KC for lysis 
by IL-2-stimulated PBMC. Effectors were added to 51 Cr-KC at the indi-
cated ratios, either without any unlabeled competing target cells (solid bars), 
or in the presence of unlabeled KC (ope11 bars) , K562 (diagot~ally striped bars), 
or Daudi (vertically striped bars). Moving from left to right for a given com-
petitor and E: T ratio, the ratios of unlabeled target to 51 Cr-KC were 30: 1, 
10: 1, and 3.3: 1 for KC and K562. Daudi competitors were always used at a 
30 : 1 ratio. (See legettd to Fig 1.) 
culture conditions could account for the conflicting results, effec-
tors were generated by culturing PBMC in 50 U /ml or 1000 U /ml 
ofiL-2 for 4 or 8 d, respectively, in each case using medium supple-
mented with FBS or PHS. These four effector populations were 
assayed agains t IFN-treatcd and nontreated KC from two donors, 
and effectors generated in the presence of FBS were assayed in 
PBS-supplemented medium as in the previous study. The LU mea-
sured against control KC vs IFN-g- treated KC fell from 40 to 7 for 
4-d effectors generated in PHS, and from106 to 63 for 4-d effectors 
generated in FBS. The LU of 8-d effectors grown with PHS and 
assayed in serum-free medium fell from 17 to 4, whereas LU of 8-d 
effectors generated and assayed in PBS-supplemented medium rose 
from 13 to 15. A second assay of these effectors against KC treated 
for 96 h with IFN-g yielded similar results. Thus, with the possible 
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Figure :\. Effect of IFN-g treatment on KC lysis by IL-2-stimulated 
PBMC. Cultured basal KC from three different donors (solid, opett, and 
striped bars, respectively} were cultured in the presence or absence of 500 
U/ml of recombinant human IFN-g for 3d before use as targets in 5 1Cr-re-
lease assays. Based on these va lues, effectors demonstrated at least 10 times 
fewer lytic units when assayed against each JFN-g-treated KC population 
than when tested against the corresponding untreated KC. (See legend to Fig 
1.} 
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Table IV. Low Concentrations ofiFN-g Induce KC Resistance 
to Lysis by IL-2-Activated PBMC• 
KC-F (Uf ml IFN-g) KC-G (U/ ml IFN-g) 
E:T 0 2.5 10 200 0 2.5 10 200 
Experiment 1 
120:1 44b 21 21 18 32 12 10 11 
60:1 34 17 20 14 23 10 6 9 
30: 1 27 12 12 9 17 7 5 8 
Experiment 2 
120 : 1 31 25 25 18 32 17 12 12 
60:1 24 19 20 13 24 12 10 8 
30 : 1 16 13 13 7 16 8 7 5 
• KC from two donors (F and G) were treated for 2 d with the indicated 
concentrations of IFN-g and used as targets for a different effector popula-
tion in each of the experiments. 
b Mean percent specific lysis of tripl icate wells (SD were < 10% of 
means, see Materials a11d Methods). 
exception of 8-d effectors cultured and assayed in medium contain-
ing FBS, IFN-g treatment reproduc1bly and markedly decreased the 
susceptibility of neonatal KC to lysis by all IL-2-stimulated PBMC 
tested in this study. 
DISCUSSION 
These studies provide information about the anti-KC effectors in-
duced by exposure of normal human PBMC to IL-2. Exogenous 
IL-2 (12 Ujml to 1000 Ujml) was required for the induction of 
anti-KC activity, and all active effector populations lysed both auto-
logous and allogeneic KC. As little as 1 d of exposure to IL-2 in-
duced anti-KC activity, whereas effector potency and yield peaked 
after 4 and 8 d of treatment, respectively. It is uncertain whether 
similar conditions of exposure to endogenously produced IL-2 
occur in vivo, as the concentration ofiL-2 experienced by anti-KC 
precursors in vivo would depend on their proximity to IL-2-
producing cells and on the balance between IL-2 production and 
consumption during a particu lar response. It is also not known 
whether KC in vivo would be lysed by IL-2- activated effectors in 
the manner reported here for cultured KC. Protocols used in many 
IL-2- based therapies, however, definitely satisfy the above criteria 
for generating anti-KC activity in vitro [32]. 
Treatment with IL-2 induces distinct T cell and non-T cell effec-
tors [22,23,30- 32]. The resistance of the anti-KC effectors to cyto-
toxic treatment with anti-CD3 antibodies indicated that they are 
mainly non-T cells (Fig 1, Table III). The minimal effect ofCD16-
depletion on anti-KC effector activity suggests that anti-KC effec-
tor precursors in PBMC are not mature CD 16 + NK cells, because 
CD16 expression is stable during stimulation w ith IL-2 [26]. The 
marked depletion of the mature anti-KC effectors by cytotoxic anti-
CD2 treatment indicates that cells with a CD2 +/CD3 -j 
CD16- phenotype account for the bulk of activity after stimula-
tion with 102 or 103 U /ml for 6 or 8 d (Results; Table III). Precursors 
of IL-2- induced anti-KC effectors were previously reported to be 
CD56+ and either CD2+ or CD2- [17]. If CD56+ precursors 
also give rise to the effectors described here, these precursors would 
presumably be among the less than 1% of CD 56 +jCD16- pe-
ripheral blood lymphocytes because, again, IL-2 treatment neither 
induces nor abrogates CD 16 expression [26]. We are currently test-
ing whether CD56 +/CD16- cells are responsible for the low 
titrating levels ofKC lysis mediated by some fresh PBMC (Table I; 
unpublished data). 
The abi lity ofK562 cells to inhibit KC lysis suggests that anti-KC 
and NK effectors may share specificities (Fig 2). The finding that 
K562 was a more effective inhibitor than KC in cold target compe-
tition assays could mean either that K562 expresses relatively more 
of a shared target antigen than KC, or that the nature or amount of 
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accessory structures involved in effector-target interactions differs 
between the two target cell rypes. Target molecules for NK and 
other non - MHC-restricted effectors have proved difficult to de-
fine, though roles for activation antigens or carbohydrates have 
been suggested [36-39]. Regarding accessory adhesion molecules, 
it was reported that ascitic fluids containing antibodies against 
LFA-1 or ICAM-1 inhibit lysis of IFN-g-treated KC by IL-2-
treated PBMC [17]. Based on these findings , it was suggested that 
LFA-1 and ICAM-1 are important for KC lysis by non-MHC-
restricted effectors. This was not directly examined in the present 
study, although the fact that the effectors in the two studies clearly 
differed in their recognition of IFN-g - treated KC indicates that 
th ese previous results may not apply to the effectors described here. 
The effect of IFN-g treatment on KC lysis by these effectors is 
further evidence of their NK-like function (Fig 3, Table III). Re-
duced 1 ysis ofiFN -g- treated endothelial cells by LAK, and ofiFN-
g- treated tumor cells by both NK and LAK effectors has been 
reported [30,31]. Studies of tumor cell variants and gene transfec-
tants strongly suggest that increased expression of conventional 
class I MHC antigens leads to decreased susceptibility to NK lysis 
[40-42]. In this context, reduced lysis ofiFN-g-treated KC could 
reflect IFN-g-induced alterations in KC class I antigen expression 
[9]. In striking contrast to its effects on non - MHC-restricted lysis, 
IFN~g treatment markedly enhances MHC-specific lysis ofKC and 
other cell types by T cells [15, 16,31]. The fact that stimulated T and 
NK cells both secrete IFN-g (43,44] suggests that IFN-g could act 
to auto-regulate KC lysis by both types of effectors, but with oppo-
site effects in each case. That is, IFN-g from NK-like cells could 
down-regulate KC susceptibility to non-MHC-restricted lysis by 
these same effectors, while simultaneously rendering antigenic KC 
more susceptible to lysis by MHC-restricted T cells. 
The report that IFN-g treatment greatly augments KC lysis by 
IL-2- activated PBMC obviously conflicts with our findings [17] . 
The discrepancy may be reconciled if one postulates that culture 
conditions used in the earlier study allowed the expansion of both 
MHC-restricted CTL and non - MHC-restricted effectors. For ex-
ample, the presence ofFBS in media used for the induction and assay 
of the effectors could have led to lysis of antigen-presenting KC by 
FBS-specific CTL. Such CTL would be expected to mediate prefer-
ential lysis ofiFN-g-treated KC, especially if they were restricted 
by class II antigens only expressed by treated KC (16]. Enhanced 
lysis ofiFN-g-treated KC by CTL could have thereby masked the 
inhibitory effect ofiFN-g treatment on non- MHC-restricted lysis. 
This explanation would fit our observation that IFN-g had less 
effect on KC lysis when effector populations were generated and 
assayed in the presence of FBS (see Results). 
The initial descriptions of IL-2- induced cytotoxic effectors, also 
ca lled lymphokine-activated kill ers (LAK), indicated that LAK lyse 
tumor cells but spare a variety of normal cell types [45,46]. Al-
though it is now known that LAK can kill certain normal cells 
[17 ,47 ,30], IL-2 and/or IL-2-activated lymphocytes have been in-
vestigated as potential cancer therapies in humans [32]. Patients in 
these clinical trials have often developed skin disease characterized 
by lymphocytic infiltrates and KC destruction [12]. The mechanism 
for this side-effect has not been established, but the observation that 
IL-2-stimulated PBMC can kill normal autologous KC in vitro 
suggests that autocytotoxic effectors could play a role ([17] , this 
paper). One function of anti-KC effectors in normal immune re-
sponses cou ld be to reduce the numbers of host cells available to 
infectious agents by ki lling healthy KC. Alternatively, non-MHC-
restricted effectors could provide an interim host lytic response to 
damaged or infected KC until specific T cells arrive at the site. 
Final ly, cytokines secreted by NK-like cells could enhance immune 
defenses in compromised skin by inhibiting viral replication and KC 
proliferation and by promoting specific lysis by T cells as discussed 
above [9,48,49]. Efforts to address these possibilities should shed 
light on the development and function of autocytotoxic anti-KC 
effectors, and on their relationship to other non-MHC-restricted 
effectors. 
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